Olivier T.
- Country
- France
- Department
- MEDICAL ONCOLOGY
Research Overview
- Evaluation of Preoperative Durvalumab (MEDI4736) in Patients with Early-Stage Untreated Small Triple Negative Breast Cancer
- Phase II Study of Durvalumab, Tremelimumab, and Olaparib in Solid Tumors with Homologous Recombination Repair Gene Mutations Post-Olaparib Response
- ISIdE: Open label, multicentric, single-arm phase IIIB trial to evaluate the safety and efficacy of sacituzumab govitecan in triple negative metastatic breast cancer patients with a biomarker analysis.
Data & Insights
Has run more than one trial at 254 of 539 partner sites.
Specializations
Triple Negative Breast Cancer
Specializes in investigating novel therapeutic approaches for triple negative breast cancer (TNBC), with particular emphasis on neoadjuvant and adjuvant treatment strategies.
- Post-operative treatment combinations
- Early detection of relapse
- Immunotherapy approaches
Focuses on developing treatment protocols for both early-stage and metastatic TNBC patients.
HER2-Related Studies
Conducts research on HER2-expressing tumors and various breast cancer subtypes, including hormone receptor-positive and HER2-negative disease.
- Advanced solid tumors
- Targeted therapies
- Combination treatments
Investigates innovative therapeutic combinations for HER2-positive and HER2-negative breast cancers.
Precision Medicine
Leads investigations in personalized treatment approaches with focus on biomarker-driven therapies and targeted interventions.
- Molecular profiling
- Immunotherapy combinations
- Treatment resistance
Develops strategies for patient-specific treatment selection and monitoring.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.